Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression-Reference-Cited by-同舟云学术

Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression

Published:2022-10-27 Issue:1 Volume:58 Page:53-68
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Sakai Norihiro,Kamimura Kenya^ORCID,Miyamoto Hirotaka,Ko Masayoshi,Nagoya Takuro,Setsu Toru,Sakamaki Akira,Yokoo Takeshi,Kamimura Hiroteru,Soki Hiroyuki,Tokunaga Ayako,Inamine Tatsuo,Nakashima Mikiro,Enomoto Hatsune,Kousaka Kazuki,Tachiki Hidehisa,Ohyama Kaname,Terai Shuji

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

https://link.springer.com/content/pdf/10.1007/s00535-022-01929-w.pdf

Reference54 articles.

1. Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut. 2018;67:963–72.

2. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9.

3. Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362–76.

4. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10.

5. Ramachandran P, Dobie R, Wilson-Kanamori JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 2019;575:512–8.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Connective Tissue Growth Factor: Regulation, Diseases, and Drug Discovery;International Journal of Molecular Sciences;2024-04-25

2. Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs;Pharmaceutics;2023-08-24

3. Prospective therapeutics for intestinal and hepatic fibrosis;Bioengineering & Translational Medicine;2023-08-02

4. 17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease;Pharmacology & Therapeutics;2023-06